

CURRICULUM VITAE

NAME: Vakaramoko (Karam), **Diaby**

BUSINESS ADDRESS: College of Pharmacy

Department of Pharmaceutical Outcomes & Policy
1225 Center Drive, HPNP Building, Rm 3317
PO Box 100496, Gainesville, FL 32610-0496
352-273-9397 office | 352-273-6270 fax

BIOGRAPHY:

Dr. Diaby is currently the Track Director, Applied Pharmacoeconomics for the UF Online Masters and an Assistant Professor of Pharmaceutical Outcomes and Policy, College of Pharmacy. Prior to joining UF, he was Assistant Professor of Health Economics and Outcomes Research in the Division of Economic, Social and Administrative Pharmacy, College of of Pharmacy and Pharmaceutical Sciences (COPPS) at Florida A&M University. Over the past 8 years, he has taught several courses targeting different audiences (Pharm D, Online Master's, and Ph.D), graduated three Ph.D. students and 1 Master's student. Since joining UF, Dr. Diaby has been advising 5 Ph.D students and 1 Masters' student. He has served on 15 Masters and Ph.D committees [5 Matser's (Chaired 3) and 10 Ph.D. (Chaired 5)]. Dr. Diaby has published over 40 peer-reviewed publications, including two book chapters. Dr. Diaby was the PI on a pilot project grant from the NIH/NIMHD, a Mitacs grant (Canada), and currently serves as a project-agnostic investigator on an NIH/NHGRI grant. Dr. Diaby recently completed a sub-award from a U54 center grant (U54OH011230) to study the impact of heat-related illness on the gross domestic product, agricultural and health sectors of the Southeastern and Coastal Center for Agricultural Health and Safety (SCCAHS)' catchment area. He is the PI on a Nicklaus Children's Hospital foundation pharmacogenomics grant and a Co-PI on an industry (Merck) contract. Dr. Diaby serves as a health economist on a HIV Telemedicine grant sponsored by the CDC. He has been contributing service to the College of Pharmacy by sitting on the curriculum and faculty governance committees. He is a grant peer-reviewer for three international agencies (UK, New Zealand and The Netherlands) and a peer-reviewer for several academic journals. Dr. Diaby was an academic editor for the journal PLOS ONE and currently serves on the editorial board of Pharmacoeconomics-Open.

EDUCATIONAL BACKGROUND:

i) Degrees:

2011 Ph.D. Pharmaceutical Sciences, Major: Drug and Population Health, Faculty of Pharmacy, University of Montreal (Quebec, Canada)

2006 M.Sc. Pharmaceutical Sciences, Major: Drug and Population Health, Faculty of Pharmacy, University of Montreal (Quebec, Canada)

2004 Clinical Research Associate Certification (CCRA), Sup Santé – Paris (France)

2003 Bachelor Biomedical Sciences, Major: Medical analyses, Faculty of Science and Technology, Hassan II Mohammadia University (Morocco)

ii) Continuing Education:

2019: International Society for Pharmacoeconomics and Outcome Research (ISPOR) 24th Annual International Meeting –New Orleans, LA, United States

2018: International Society for Pharmacoeconomics and Outcome Research (ISPOR) 23rd Annual International Meeting -Baltimore, MD, United States

2017: International Society for Pharmacoeconomics and Outcome Research (ISPOR) 22nd Annual International Meeting -Boston, MA, United States

2016: Online Course - Econometrics: Theory and Application (Coursera - Erasmus University, Rotterdam, Netherlands)

2015: Workshop: Multi-Criteria Decision Analysis for Healthcare (Springer Book writing meeting - Amsterdam, Netherlands)

2014: 36th Annual meeting of the Society for Medical Decision Making, Miami, FL, US

2014 International Society for Pharmacoeconomics and Outcome Research (ISPOR) 19th Annual International Meeting -Montreal, QC, Canada

2013 35th Annual meeting of the Society for Medical Decision Making, Baltimore, MD, US

2013 11th McMaster Clinical Epidemiology & Biostatistics research day, Hamilton, ON, Canada

2012 Online Training: Multi-Criteria Decision Analysis - Elementary and advanced methods (VRTUOSI: www.vrtuosi.com/)

2012 Workshop: Advanced decision modeling for health economic evaluation (International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting -Washington, DC, USA)

2012 Workshop: Introduction to decision modeling for health economic evaluation (International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting - Washington, DC, USA)

2012 Workshop: Conjoint Analysis Theory (International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting -Washington, DC, USA)

2012 Workshop: Advanced pharmacoeconomics (Canadian Association for Population Therapeutics Annual Conference – Montreal, QC, Canada)

2012 Workshop: Introduction to pharmacoepidemiology (Canadian Association for Population Therapeutics Annual Conference – Montreal, QC, Canada)

2012 McMaster Clinical Epidemiology & Biostatistics research day, Hamilton, ON, Canada

2012 Seminar: Intravenous Thrombolysis vs. Best Medical Treatment for Late-Presentation Acute Ischemic Stroke - An Economic Evaluation in a Canadian Setting; Hamilton, ON, Canada

2011 Seminar: Oncotyrol the centre for personalized cancer research – Current research

2011 Seminar: Using Reference Manager 12 (RM12) tool in a networked environment

2011 Workshop: Health Technology Assessment: From Theory to Evidence to Policy (Programs for Assessment of Technology in Health Research Institute)

2011 Health Technology Assessment: From Theory to Evidence to Policy, Toronto, On, Canada

2004-2011 Seminars in Pharmaceutical Sciences (Attendance to over 40)

EMPLOYMENT HISTORY:

i) Academic:

07/2017 University of Florida, Gainesville
Assistant Professor of Pharmaceutical Outcomes and Policy, College of Pharmacy, Gainesville, Florida

09/2013 Florida A&M University, Tallahassee, Florida
Assistant professor of Pharmaceutical Sciences (Pharmacoeconomics and outcomes research)

2013 McMaster University, Hamilton (Ontario, Canada)/PATH Research Institute
Sessional lecturer (with Professor Jean-Eric Tarride) - HRM 740: Advanced Decision Analysis in Health Technology Assessment (Health Technology Assessment)

2012 McMaster University, Hamilton (Ontario, Canada) Hamilton (Ontario, Canada)/PATH Research Institute
Sessional lecturer (with Professor Jean-Eric Tarride) - HRM 740: Advanced Decision Analysis in Health Technology Assessment

2008–2009 (6 months) Graduate Research Assistant, University of Montreal, Ste Justine Hospital of Montreal, Quebec, Canada

ii) Consultations (Biotech industry):

2004 Clinical Research Associate (CRA), RMF DICTAGENE SA, Lausanne – Vaud-Switzerland

SCHOLARLY AND PROFESSIONAL ACTIVITIES:

i) Membership to Editorial Boards

Academic Editor, PLOS ONE (Effective 2018)

Editorial board member, Pharmacoeconomics – Open (Effective 2016)

ii) Peer-Review Journal Referee

2019 Referee for several peer-reviewed journals including Annals of internal medicine, Drugs and Aging, Pharmacoeconomics, Pharmacoeconomics – Open, PloS One

2018 Referee for several peer-reviewed journals including BMJ open, Expert Review of Pharmacoeconomics and Outcomes Research, Medical Decision Making, Patient-centered outcomes research, Inquiry

2017 Referee for several peer-reviewed journals including BMJ open, Expert Review of Pharmacoeconomics and Outcomes Research, Medical Decision Making, Patient-centered outcomes research, Inquiry - ISPOR-Europe

2016 Referee for several peer-reviewed journals including JAMA Oncology, BMC Cancer, Breast Cancer Research and Treatment, Pharmacoeconomics, Applied Health Economics and Health Policy, Value in Health, Expert Review of Pharmacoeconomics and Outcomes research, Inderscience

2015 Referee for BMC Health Services Research, Breast Cancer Research, and Treatment, Pharmacoeconomics, Applied Health Economics and Health Policy, Expert Opinion On Pharmacotherapy, ISPOR MCDA Task Force - ISPOR–North America

2014 Referee for several peer-reviewed journals including Patient: Patient-centered outcomes research, Medical Decision Making, Cost-effectiveness, and Resource Allocation, Annals of Internal Medicine, Health Services Insights, BMC Health Services Research, Systematic Reviews, The Breast, Pharmacoeconomics and Quality of Life Research, ISPOR–Europe

2013 Referee for European Journal of Health Economics, Operations Research in Health Care, Dove medical press, Patient: Patient-centered outcomes research, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)–Europe

2012 Pharmacy Practice

iii) Peer-Review - Grants

2020 NWO Talent Programme – Veni scheme – ZonMw – The Netherlands

2018 Academy of Medical Sciences - United Kingdom

2018 Health Research Council - New Zealand

iv) Membership to Professional Societies and Certifications

1. Member, International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
2. Member, American Association for Cancer Research (AACR)
3. Certified Clinical Research Associate (CCRA)

HONOURS & FELLOWSHIPS:

2019: Systematic Reviews With Cost And Cost-Effectiveness Outcomes Good Practices Task Force

2017: Podium presentation award finalist (Presented by Dr. Askal Ali) - International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conference – North America 2017

2016 Highly Cited Research in Operations Research For Healthcare

2016 Teacher of the Year 2015, Florida A&M University
 2015: Interview with the Globe and Mail about research in geriatric pharmacoeconomics
 2015 Teacher of the Year 2014, Florida A&M University
 2015 Elsevier Reviewer Recognition
 2013 Abstract selection for the Presidential Poster Section by the American Geriatrics Association
 2012 Mitacs Accelerate Award
 2012 Bernie O'Brien Post-Doctoral Fellowship Award
 2011 Recommendation to the Dean's Honour List for Doctoral Thesis
 2011 Pfizer Postdoctoral Fellowship in Health Economics
 2006 Canadian Association for Population Therapeutics (CAPT) Studentship Award

OTHER EDUCATIONAL CONTRIBUTIONS

i) Undergraduate:

2009 Introduction to Pharmacoeconomics, tutor, 1 term, Faculty of Pharmacy, University of Montreal 16 h

TOTAL EDUCATION HOURS:

2009 Introduction to Pharmacoeconomics, tutor, 1 term, Faculty of Pharmacy, University of Montreal 16 h

RESEARCH FUNDING (GRANTS):

Ongoing Research Support

PRO00028659	Diaby (PI)	1/1/2020	12/31/2020
Nicklaus Children's Hospital			
Epidemiology and cost of RSV infections in infants and toddlers			98,757
Role: Co-PD/PI			
PRO00023980	Winterstein (PI)	3/1/2020	03/31/2020
MERCK AND COMPANY INC			
Economic evaluation of rapid whole-genome sequencing (rWGS) in critically ill children: the case of the Nicklaus Children's hospital			229,346.00
Role: Co-PD/PI			
PRO00024515	Johnson (PI)	7/1/2019	6/30/2023
National Institutes of Health			
Sparkling Advancements in Genomic Medicine-Supplement-GUARDD			5,308,694.00
Role: Co-Investigator:			
PRO00016168	Johnson (PI)	7/1/2018	6/30/2023
National Institutes of Health, National Human Genome Research Institute			
Sparkling Advancements in Genomic Medicine			3,429,433.00
Role: Other Non-Key Personnel			

Pending Research Support

PRO00028918 **Diaby (PI)** **07/1/2020** **6/30/2023**
American Cancer Society
CDK 4/6 inhibitors in breast cancer: real-world assessments of effectiveness 580,532.00

Submitted - But Not Funded

PRO00025992 **Diaby (PI)** **4/1/2020** **3/31/2023**
NATL INST OF HLTH NCI
Real-world patterns, adherence, clinical and economic outcomes associated with palbociclib for ER-positive metastatic breast cancer in elderly patients 1,487,279.00

PRO00028708 **Diaby (PI)** **1/1/2020** **12/31/2020**
PhRMA Foundation
A patient-centered decision tool for value-based prevention choices for women at high risk of developing breast cancer 99,496.00

PRO00020458 **Diaby (PI)** **12/1/2018** **11/30/2020**
Russell Sage Foundation
Modeling and predicting policy change with social media using machine learning: Case of medical marijuana legalization in the United States 142,673.00

PRO00022660 **Diaby (PI)** **7/1/2019** **6/30/2021**
NATL INST OF HLTH
Multipolicy effects on outcomes in people with co-occurring alcohol and other drug use disorders: An agent-based input-output modeling framework 419,375.00

PRO00020514 **Diaby (PI)** **1/1/2019** **12/31/2021**
US DEPT OF DEFENSE
Anti-HER2 targeted therapy in breast cancer: patterns of care 552,372.00

PRO00020964 **Diaby (PI)** **4/1/2019** **3/31/2021**
National Institutes of Health, National Cancer Institute
Eliciting preferences towards attributes of decision making about chemoprevention in women at high-risk for breast cancer: A discrete choice experiment 152,500.00

PRO00023609 **Diaby (PI)** **1/1/2019** **9/30/2020**
FLORIDA A&M UNIVERSITY
An evaluation of pharmacogenomic screening integrated with medication therapy management in medically underserved 17,848.00

Completed Research Support

U54OH011230 **Morris (PI)** **09/01/2016 - 09/30//2021**
CTRS FOR DIS CNTRL INST OCCUP SFTY HLTH
Southeastern and Coastal Center for Agricultural Health and Safety (SCC-AHS) (AWD00538) 30,233
Role: PI (Sub-award) **07/01/2019 - 09/30//2019**

2G12MD007582 **Soliman (PI)** **04/01/15-03/31/16**

NIH/NIMHD/RCMI

RCMI Pharmaceutical Research Center - Administrative Core

Faculty Development - Pilot Project Program

Assessing the Benefits of Cancer Treatments Using Quality-Adjusted Progression-Free Survival

Role: Pilot Project PI

Canadian Institute of Health Research

Xie (PI)

02/01/12 - 01/31/2014

Improving patient-reported outcome measures to support evidence-based decision making: establishing measurement properties of the EQ-5D.

Role: Co-Investigator

Mitacs Grant

Diaby (PI)

2/01/12 - 08/31/13

Multi-Criteria Decision Analysis (MCDA) as an Alternative Decision-Making Framework for Health Technology Assessment in Canada

Pfizer Postdoctoral Fellowship in Health Economics

Diaby (PI)

10/2011-09-2012

The goal of this project was to pilot test the use of Multi-Criteria Decision Analysis (MCDA) as a support tool in health technology assessment in Canada.

LIFETIME PUBLICATIONS:

i) PEER-REVIEWED:

a) Journal Articles:

1. Babcock A, Askal AA, Balkrishnan R, Montero AJ, **Diaby V**. Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER-2 Negative Metastatic Breast Cancer: A commentary. Accepted J Manag Care Spec Pharm, 13 February 2020. **IF: 3.02**
2. **Diaby V**, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. The Breast. 2020 Feb 1; 49: 141-148. doi: doi.org/10.1016/j.breast.2019.11.012. PMID:31805500. **IF: 3.494**
3. Tran AD, Fogarty G, Nowak AK, **Diaby V**, Hong A, Watts C, Morton RL. Cost-effectiveness of subsequent hippocampal-avoidant whole brain radiotherapy versus stereotactic radiosurgery or surgery alone, for treatment of melanoma brain metastases. Accepted Applied Health Economics and Health Policy, 22 January 2020. **IF: 2.664**
4. **Diaby V**, Wang CY, Alqhtani H, van Boemmel-Wegmann S, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting. Data Brief. 2020 Jan 25;29:105194. doi: 10.1016/j.dib.2020.105194. PMID: 32071975; **CiteScore: 0.93**
5. Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, **Diaby V**, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates

- Among Patients with Atrial Fibrillation in the United States. *Clin Transl Sci.* (2020) doi:[10.1111/cts.12719](https://doi.org/10.1111/cts.12719). PMID: 32053288. **IF: 3.989**
6. Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, **Diaby V**, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF; Implementing GeNomics In practice (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx). Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. *Pharmacogenomics J.* 2020 Feb 11. doi: 10.1038/s41397-020-0162-5. [Epub ahead of print] PMID: 32042096. **IF: 3.503**
 7. Baltussen R, Marsh K, Thokala P, **Diaby V**, Castro H, Cleemput I, Garau M, Iskrov G, Olyaeemanesh A, Mirelman A, Mobinizadeh M, Morton A, Tringali M, van Til J, Valentim J, Wagner M, Youngkong S, Zah V, Toll A, Jansen M, Bijlmakers L, Oortwijn W, Broekhuizen H. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. *Value in Health.* 2019; 22(11):1283-1288. doi:10.1016/j.jval.2019.06.014. PMID: 31708065. **IF: 5.037**
 8. Ali AA, Tawk R, Xiao H, Campbell E, Semykina A, Montero AJ, Mogos M, **Diaby V**. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. *Cancer Med.* 2018 Dec 12. DOI: 10.1002/cam4.1904; PMID: 30548840. **IF: 3.357**
 9. **Diaby V**, Ali AA, Montero AJ. Value Assessment Frameworks in the United States: A Call for Patient Engagement. *PharmacoEconomics Open.* 2019. 3: 1–3. doi:10.1007/s41669-018-0094-z. PMID: PMID: 30182346; **IF: Not available**
 10. Xiao H, Jiang X, Chen C, Montero AJ, **Diaby V**. Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. *Pharmacoecon Open.* 2018 Dec;2(4):359-369. doi: 10.1007/s41669-018-0070-7. Review. PMID: 29470807; **IF: Not available**
 11. Okere AN, Ezendu K, Berthe A, **Diaby V**. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. *J Manag Care Spec Pharm.* 2018 Feb;24(2):142-152. doi: 10.18553/jmcp.2018.24.2.142. PMID: 29384027. **IF: 3.02**
 12. **Diaby V**, Ali AA, Williams KJ, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. *Breast Cancer Res Treat.* 2017 Dec;166(3):951-963. doi: 10.1007/s10549-017-4473-4. Epub 2017 Aug 24. PMID: 28840424. **IF: 3.471**
 13. Okere AN, Montesdeoca J, Glasper A, **Diaby V**. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review. *Curr Diabetes Rev.* 2018;14(4):363-375. doi:10.2174/1573399813666170724113240. Review. PMID: 28738763. **IF: Not available**

14. Ali AA, Xiao H, Tawk R, Campbell E, Semykina A, Montero AJ, **Diaby V**. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. *Curr Med Res Opin*. 2017 Feb;33(2):391-400. doi: 10.1080/03007995.2016.1257983. Epub 2016 Dec 8. PMID: 27819160. **IF: 2.345.**
15. Boulin M, **Diaby V**, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. *PLoS One*. 2016 Sep 20;11(9):e0162951. doi: 10.1371/journal.pone.0162951. eCollection 2016. [PMID: 27648831. **IF: 2.776.**
16. **Diaby V**, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. *Breast Cancer Res Treat*. 2016 Nov;160(1):187-196. Epub 2016 Sep 21. PMID: 27654970. **IF: 3.471**
17. **Diaby V**, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. *Curr Med Res Opin*. 2016 Jun;32(6):991-6. doi: 10.1185/03007995.2016.1149056. Epub 2016 Mar 2. PMID: 26824145; Central PMCID: PMC4959115. **IF: 2.345.**
18. Ali AA, Xiao H, Campbell ES, **Diaby V**. Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation. *Pharm Med* 29, 247–253 (2015). doi:10.1007/s40290-015-0113-7 **IF: Not available**
19. **Diaby V**, Sanogo V, Moussa KR. ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare. *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(1):141-7. doi:10.1586/14737167.2015.1083863. Epub 2015 Sep 1. PMID: 26361235; PMCID: PMC4753097. **IF: 1.828**
20. Tannenbaum C, **Diaby V (Co-first author)**, Singh D, Perreault S, Luc M, Vasiliadis HM. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. *Drugs Aging*. 2015 Apr;32(4):305-14. doi: 10.1007/s40266-015-0251-3. PMID: 25825121. **IF: 3.221**
21. **Diaby V**, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. *Breast Cancer Res Treat*. 2015 May;151(1):27-40. doi:10.1007/s10549-015-3383-6. Epub 2015 Apr 19. Review. PMID: 25893588. **IF: 3.471**
22. Adunlin G, **Diaby V**, Xiao H. Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis. *Health Expect*. 2015 Dec;18(6):1894-905. doi: 10.1111/hex.12287. Epub 2014 Oct 18. Review. PMID: 25327341. **IF:2.847**
23. **Diaby V**, Goeree R, Hoch J, Siebert U. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. *Expert Rev Pharmacoecon Outcomes Res*. 2015 Feb;15(1):13-9. doi:10.1586/14737167.2015.965155. Epub 2014 Sep 30. PMID: 25267699. **IF: 1.828**

24. **Diaby V**, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. *Breast Cancer Res Treat.* 2014 Aug;146(3):669-73. doi: 10.1007/s10549-014-3047-y. Epub 2014 Jul 14. PMID: 25017612. **IF: 3.471**
25. **Diaby V**, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. *Breast Cancer Res Treat.* 2014 Sep;147(2):433-41. doi: 10.1007/s10549-014-3042-3. Epub 2014 Jul 11. Erratum in: *Breast Cancer Res Treat.* 2014 Sep;147(2):443. PMID: 25012857. **IF: 3.471**
26. **Diaby V**, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. *Pharmacoeconomics.* 2014 Feb; 32(2):101-8. doi: 10.1007/s40273-013-0123-9. PMID: 24338265. **IF: 3.705**
27. Adunlin G, **Diaby V**, Montero AJ, Xiao H. Multicriteria decision analysis in oncology. *Health Expect.* 2015 Dec;18(6):1812-26. doi: 10.1111/hex.12178. Epub 2014 Mar 17. Review. PMID: 24635949. **IF:2.847**
28. **Diaby V**, Goeree R. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. *Expert Rev Pharmacoecon Outcomes Res.* 2014 Feb;14(1):81-99. doi:10.1586/14737167.2014.859525. Epub 2013 Dec 13. Review. PMID: 24328890. **IF: 1.828**
29. Goeree R, **Diaby V**. Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? *Best Pract Res Clin Gastroenterol.* 2013 Dec;27(6):831-44. doi: 10.1016/j.bpg.2013.08.016. Epub 2013 Sep 26. Review. PMID: 24182604. **IF: 3.583**
30. Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, Kind P, Goetghebeur MM, International Task Force on Decision Criteria (including: Ferraz MB, Carrasqueiro S, Chinitz D, Chitama D, Clifford T, Cumming J, **Diaby V**, Flamion B, Gerber-Grote A, Goeree R, Guindo A, Harstall C, Jacobs P, Jehu-Appiah C, Kletchko S, Lettieri E, Longworth L, Martin J, McDonald K, Miot J, Niessen L, Paolucci F, Peacock S, Poulin P, Raisch DW, Rajasekaran S, Ryan F, Siebert U, Tringali M, Waldau S, Wong P). Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers [In Press]. *Int J Technol Assess Health Care.* 2013 Oct; 29(4):456-65. doi: 10.1017/S0266462313000573. PMID: 24290340. **IF: 1.418**
31. Adunlin G, Xiao H, **Diaby V***. Exploring the state of pharmacy profession: The perspective of Côte d'Ivoire. *Currents in Pharmacy Teaching and Learning.* 2013; 5(5): 470- 476. doi:10.1016/j.cptl.2013.06.005. **CiteScore: 0.75**
32. **Diaby V**, Campbell K, Goeree R. (2013). Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis. *Operations Research for Health Care.* Mar 2013; 2(1): 20-24. doi:10.1016/j.orhc.2013.03.001. **CiteScore: 2.59**
33. **Diaby V**, Lachaine J. An application of a proposed framework for formulary listing in low-

income countries: the case of Côte d'Ivoire. *Appl Health Econ Health Policy*. 2011 Nov 1;9(6):389-402. doi: 10.2165/11595220-000000000-00000. PMID: 22017499. **IF: 2.664**

34. **Diaby V**, Dié Kakou H, Lachaine J. Eliciting preferences for reimbursed drugs selection criteria in Côte d'Ivoire. *Patient*. 2011;4(2):125-31. doi:10.2165/11586060-000000000-00000. Erratum in: *Patient*. 2011;4(2):132. PMID: 21766901. **IF: 2.673**
35. **Diaby V**, Laurier C & Lachaine J. A Proposed Framework for Formulary Listing in Low-Income Countries. *Pharm Med*. 2011; 25: 71–82. doi:10.1007/BF03256848. **IF: Not available**
36. **Diaby V**, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. *Maturitas*. 2007 Oct 20;58(2):138-49. Epub 2007 Sep 17. **IF: 3.654**

b) Letters to the Editor

1. Tran PT, **Diaby V**. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. *J Manag Care Spec Pharm*, 2020 Feb;26(2):221-221. doi:10.18553/jmcp.2020.26.2.221. **IF: 3.02**
2. **Diaby V**, Adunlin G, Montero AJ. Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. *J Med Econ* 2014;16(2):278-88. *J Med Econ*. 2014 Apr;17(4):248-9. doi: 10.3111/13696998.2014.892883. Epub 2014 Feb 20. PMID: 24506762. **IF: 1.885**

c) Errata

1. **Diaby V**, Kakou HD, Lachaine J. Erratum to: Eliciting Preferences for Reimbursed Drugs Selection Criteria in Côte d'Ivoire. *Patient*. 2011; 4(2), 132-132. **IF: 2.673**
2. **Diaby V**, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. *Breast Cancer Res Treat*. 2014; 147(2), 443-443. **IF: 3.471**

a) Accepted and published book chapters

1. **Diaby V**, Goeree R., 2016. Coverage with Evidence Development in Comparative Effectiveness Research. *Comparative Effectiveness Research in Health Services*. pp.291-306.
2. **Diaby V**, Dias L., 2017. Beyond Value Function Methods in MCDA for Health Care. In *Multi-Criteria Decision Analysis to Support Healthcare Decisions*. Springer International Publishing. pp. 299-310.

f) Preprints

1. **Diaby V**, Sanogo V, Xiao H, Zhong X, Dykes J, Judson C. Economic Impact of the Passage of

the Medical Marijuana Law in the State of Florida (October 12, 2018). Available at SSRN: <http://dx.doi.org/10.2139/ssrn.3265254>

2. Moussa K Richard, **Diaby V**. A Study on Self-Assessed Life Expectancy Among Older Adults in Côte d'Ivoire. (March 2020) DOI: 10.21203/rs.3.rs-15595/v1

g) Podium presentations

1. **Diaby V** (February, 2020). Overview of Multi-criteria Decision Analysis (MCDA) & Its applications in Health Technology Assessment (HTA). **Invited presentation** – ISPOR Student Network Educational Webinar. Link ([https://www.ispor.org/member-groups/students/webinars/webinar/overview-of-multi-criteria-decision-analysis-\(mcda\)-its-applications-in-health-technology-assessment-\(hta\)](https://www.ispor.org/member-groups/students/webinars/webinar/overview-of-multi-criteria-decision-analysis-(mcda)-its-applications-in-health-technology-assessment-(hta)))
2. **Diaby V** (September, 2019). Genomics in Medicine and Health? **Invited presentation** – National Human Genome Research Institute, Bethesda, September 26-27th, 2015. Link (<https://youtu.be/WS8J5dQ-VBU>)
3. **Diaby V** (August, 2019). Is Economics relevant for the frontline clinician **Invited presentation** – *Nicklaus Children's Hospital*.
4. **Diaby V** (June, 2015). Beyond value function methods in Multi-Criteria Decision Analysis for Healthcare? **Invited presentation** – *IGH-CIHR National Stakeholders' meeting to reduce over-prescription of drugs to seniors, Women's College Hospital, Toronto, January 23rd, 2015*.
5. **Diaby V** (January, 2015). Reducing over-prescription of drugs to seniors: The question isn't whether to do it – It's How to do it? **Invited presentation** – *IGH-CIHR National Stakeholders' meeting to reduce over-prescription of drugs to seniors, Women's College Hospital, Toronto, January 23rd, 2015*.
6. **Diaby V** (2014, October). Cost-effectiveness analysis of metastatic breast cancer treatments: A study based on the bolero-2 trial. In *The 36th Annual Meeting of the Society for Medical Decision Making. SMDM*.
7. **Diaby V** (2013, May). Current state of research on alternative decision-making framework for HTA. **Invited presentation** – *CADTH Symposium, Delta St John's, Newfoundland, May 5, 2013*.
8. **Diaby V** (2013, April). Multi criteria decision analysis, a framework for drug reimbursement decision making. **Guest speaker** - *Pfizer educational rounds, Pfizer Head Office, Montreal, QC, April 16, 2013*.
9. **Diaby V** (2012, November). Methods for the development of formularies in developing countries. **Invited presentations** - *Mutuelle des Fonctionnaires et Agents de l'Etat de Côte d'Ivoire, Abidjan, Côte d'Ivoire, September 17 – November 05 2012*.
10. **Diaby V** (2012, July). Potential Strengths and Limitations of Multi-Criteria Decision

Analysis for Use in Decision-Making Frameworks. **Invited presentation** - Decision Determinant Committee, Health Quality Ontario, Toronto, ON, July 10, 2012.

11. **Diaby V** (2012, April). Using Multi-Criteria Decision Analysis to Inform Healthcare Decision-Making in Canada: A Post-Doctoral Fellow's Perspective. **Invited presentation** - Pfizer Research Exchange Dinner, Westin Hotel, Ottawa, ON, April 16, 2012.

j) Poster presentations and Published Abstracts:

1. **Diaby V**, Ali AA, Montero AJ. Value Assessment Frameworks in the United States: A Call for Patient Engagement. *Pharmacoecon Open*. 2019 Mar;3(1):1-3. doi:10.1007/s41669-018-0094-z. PMID: 30182346; PMCID: PMC6393280.
2. Huang Y, Yu Y, **Diaby V**. (2019) Cost-effectiveness study of immune checkpoint therapy in advanced non-small cell lung cancer (nscl): a systematic literature review. *ISPOR Europe 2019*.
3. Ezendu KO, Ali AA, **Diaby V**. Cost-effectiveness of adjuvant whole breast irradiation. *Pharmacoepidemiology and drug safety*. 2019; 28:295-296.
4. Moussa RK, **Diaby V**. Self-Assessed Life Expectancy Among the Elderly in Developing Countries: Evidence From Côte D'ivoire. 2018; *Value in Health*. 21: S227.
5. Chen Z, Xiao H, **Diaby V**. PCN146-inotuzumab ozogamicin in patients with relapsed or refractory (r/r) acute lymphocytic leukemia (all): establishing a value-based cost-preliminary results. 2018; *Value in Health*. 21: S39.
6. Ezendu KO, **Diaby V**, Ali AA. Lifetime Cost-Effectiveness of Adjuvant External Beam Whole Breast Irradiation (EBWBI) in Estrogen Receptor Positive (ER+) Early-Stage Breast Cancer (ESBC) Women: Cardiotoxicity Consideration. *Value in Health* 21 (2018): S33.
7. Ali AA, Xiao H, Tawk RH, Campbell ES, Semykina A, Montero AJ, **Diaby V**. Comparative cost-effectiveness of early-stage breast cancer treatments in the elderly. *Value in Health*. 2017; 20(5):A9.
8. Jackson M, Williams K, Ali AA, **Diaby V**. The Feasibility of Utilizing Pharmacogenomics-Based Testing Techniques in the Treatment of HIV/AIDS: A Systematic Review. *Value in Health*. 2018; 21: S153.
9. Ali AA, Xiao H, Tawk RH, Campbell ES, Semykina A, Montero AJ, **Diaby V**. Comparative cost-effectiveness of early-stage breast cancer treatments in the elderly. *Value in Health*. 20 (5): A9.
10. **V Diaby**, V Sanogo, RK Moussa. An alternative weight elicitation method for use in multi-criteria decision analysis for healthcare. *Value in Health*. 20 (5): A337.
11. **Diaby V**, Adunlin G, Ali A, Zeichner S, Lopes G, Kohn CG, Montero AJ. Cost Effectiveness of Different Targeted Treatment Sequences for HER2-Positive Metastatic Breast Cancer. *Value in Health*. 2016 May 1;19(3):A150.

12. Ali AA, Adunlin G, Xiao H, **Diaby V***. Reconstruction of individual patient data based on published Kaplan-Meier curves: Case of regorafenib for colorectal cancer. *Value in Health*. 2015 May 1;18(3):A19.
13. Ali AA, **Diaby V**, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic HER2-positive breast cancer patients. *Value in Health*. 2016; 19(3): A88.
14. Adunlin G, **Diaby V**, Campbell ES, Xiao H, Montero AJ, Dranitsaris G. A Multi-Criteria Decision Making Approach for Selecting an Optimal Therapy for Metastatic Colorectal Cancer. *Value in Health*. 2016; 19(3): A169-A170.
15. Ali AA, Adunlin G, Tawk R, **Diaby V**. Estimation of the Quality Adjusted Progression Free Survival of the Treatment Arms of the Bolero-2 Trial. *Value in Health*. 17 (3): A89
16. Adunlin G, **Diaby V**, Montero A, Xiao H. Multi-criteria decision analysis in oncology: an overview. *Value in Health*. 17 (3): A184
17. **Diaby V**. Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial. The 19th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. *ISPOR. Montreal, QC*, May 31 – June 04, 2014
18. **Diaby V**. How can Multi-criteria Decision Analysis (MCDA) lend support to decision making in health technology assessment (HTA). *In The 35th Annual Meeting of the Society for Medical Decision Making. SMDM. Baltimore, MD*, October 19-23, 2013
19. **Diaby V**, Lachaine J, Die Kakou H. Eliciting Preferences for Reimbursed Drugs Selection Criteria in Côte d'Ivoire. Poster presentation at the *ISPOR 17th Annual International Meeting*, Washington, DC, June 2-6, 2012.
20. **Diaby V**, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: The case of Côte d'Ivoire. Poster presentation at the *ISPOR 14th European Congress*, Madrid, Spain, 5-8 November 2011. *Value in Health* (Vol. 14, Issue 7, Page A423, DOI: 10.1016/j.jval.2011.08.1043).
21. **Diaby V**, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: The case of Côte d'Ivoire. 7th RQRUM annual meeting, Quebec, QC, Canada, June 1st-2 2011. (*J Popul Ther Clin Pharmacol* Vol 18(2):e275-e314; May 19, 2011).
22. **Diaby V**, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. *Can J Clin Pharmacol* Vol 13(1) Winter 2006: e128-e227; May 8, 2006.